Revenue

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

Fresh off its spin-off, the US metals processor is in talks to acquire a German giant, a move that could reshape the global steel industry.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

AMC sells its Hycroft Mining stake to gold titan Eric Sprott for $24.1M, ending a curious diversification to double down on its core cinema business.

With shareholder approval secured, the HNI-Steelcase merger is set to create a $5.8B powerhouse. But can it deliver on its $120M synergy promise?

A 209kg opium seizure reveals how Canada's billion-dollar investment in AI and intelligence is disrupting sophisticated global drug smuggling networks.

Designer Hiromi Asai redefines Japanese heritage at Miami Art Week, transforming sacred kimono textiles into sculptural menswear and making a bold market play.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

A Canadian firm's breakthrough promises to produce renewable natural gas at price parity with fossil fuels. Is this the key to unlocking a greener economy?

A smart appliance company is upending global expansion by proving that listening to local communities is the key to becoming a brand that truly matters.

USA Pickleball's exclusive DUPR deal aims to unify the sport, but a single rating system brings both professional legitimacy and player controversy.

A new national strategy combines massive insurance expansion with targeted educational funding to fix Canada’s oral health crisis and ease ER pressure.

Following a strategic merger, the National Down Syndrome Society appoints six new leaders, signaling a new era of inclusive, research-driven advocacy.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

In a powerful move, Ashkenazy Acquisition Corp. acquires a major Chicago retail center, part of a $750M spree that defies market doomsayers.

The Dot Corp's new division signals a major shift in marketing logistics. Why are companies abandoning siloed vendors for a single source of truth?

A utility is slashing its carbon footprint by 99.9% not with solar or wind, but with an invisible innovation that fixes the grid from the inside out.

Chile's state oil firm is using strong profits to buy back $150M in debt. Is this just smart accounting, or a move to fund its green hydrogen ambitions?